Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT | Zendy

Matthew Scarborough | Zendy; Ho Kwong Li | Zendy; Ines Rombach | Zendy; Rhea Zambellas | Zendy; A. Sarah Walker | Zendy; Martin McNally | Zendy; Bridget L. Atkins | Zendy; Michelle Kümin | Zendy; Benjamin A. Lipsky | Zendy; Harriet Hughes | Zendy; Deepa Bose | Zendy; Simon Warren | Zendy; Damien Mack | Zendy; Jonathan Folb | Zendy; Elinor Moore | Zendy; Neil Jenkins | Zendy; Susan Hopkins | Zendy; R.A. Seaton | Zendy; Carolyn Hemsley | Zendy; Jonathan Sandoe | Zendy; Ila Aggarwal | Zendy; Simon Ellis | Zendy; Rebecca Sutherland | Zendy; Claudia Geue | Zendy; Nicola McMeekin | Zendy; Claire Scarborough | Zendy; John R. Paul | Zendy; Graham Cooke | Zendy; Jennifer Bostock | Zendy; Elham Khatamzas | Zendy; Nick Wong | Zendy; Andrew Brent | Zendy; José Manuel Lomas | Zendy; Philippa C. Matthews | Zendy; Tri Wangrangsimakul | Zendy; Roger Gundle | Zendy; Mark Rogers | Zendy; Adrian Taylor | Zendy; Guy Thwaites | Zendy; Philip Bejon | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral versus intravenous antibiotics for bone and joint infections: the OVIVA non-inferiority RCT

Author(s) -

Matthew Scarborough,

Ho Kwong Li,

Ines Rombach,

Rhea Zambellas,

A. Sarah Walker,

Martin McNally,

Bridget L. Atkins,

Michelle Kümin,

Benjamin A. Lipsky,

Harriet Hughes,

Deepa Bose,

Simon Warren,

Damien Mack,

Jonathan Folb,

Elinor Moore,

Neil Jenkins,

Susan Hopkins,

R.A. Seaton,

Carolyn Hemsley,

Jonathan Sandoe,

Ila Aggarwal,

Simon Ellis,

Rebecca Sutherland,

Claudia Geue,

Nicola McMeekin,

Claire Scarborough,

John R. Paul,

Graham Cooke,

Jennifer Bostock,

Elham Khatamzas,

Nick Wong,

Andrew Brent,

José Manuel Lomas,

Philippa C. Matthews,

Tri Wangrangsimakul,

Roger Gundle,

Mark Rogers,

Adrian Taylor,

Guy Thwaites,

Philip Bejon

Publication year - 2019

Publication title -

health technology assessment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.426

H-Index - 126

eISSN - 2046-4924

pISSN - 1366-5278

DOI - 10.3310/hta23380

Subject(s) - medicine , randomized controlled trial , antibiotics , clinical endpoint , quality of life (healthcare) , physical therapy , surgery , nursing , microbiology and biotechnology , biology

Management of bone and joint infection commonly includes 4-6 weeks of intravenous (IV) antibiotics, but there is little evidence to suggest that oral (PO) therapy results in worse outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research